Literature DB >> 9664140

Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines.

E Selzer1, H Schlagbauer-Wadl, I Okamoto, H Pehamberger, R Pötter, B Jansen.   

Abstract

In human melanoma no complete information about the expression of the apoptosis-promoting and apoptosis-inhibiting members of the Bcl-2 family has been available to date. In this study we have investigated by Western blotting the expression pattern of Bcl-2 and its homologues Bax, Bak, Bcl-xL, Bcl-xS, Mcl-1 and Bad in 12 distant lymph node metastases from patients who have been treated by different regimes, in nine newly established cell lines of these metastases, in three cell lines obtained from other sources and in primary melanocytic cell lines from three neonatal and two adult subjects. Taken together, our data suggest that Bax, Bak, Bad, Bcl-xL and Mcl-1 are expressed in addition to Bcl-2 in both normal melanocytes and in cell lines established from melanoma metastases. Regarding the role of Bcl-2 and its homologues, our data suggest that expression of this class of proteins is widespread and qualitatively similar in melanoma cell lines and normal human melanocytes. Although the expression of these proteins might affect growth behaviour and the progression of melanomas, our results are not compatible with the hypothesis that the Bcl-2 homologues investigated play a dominant role in the process of malignant transformation of melanocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9664140     DOI: 10.1097/00008390-199806000-00001

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  22 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Control of experimental melanoma by host CXCR2.

Authors:  Kim A Margolin
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

Review 3.  Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.

Authors:  S Wu; R K Singh
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

4.  Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.

Authors:  Emma J Dean; Jeff Cummings; Anne Roulston; Mark Berger; Malcolm Ranson; Fiona Blackhall; Caroline Dive
Journal:  Neoplasia       Date:  2011-04       Impact factor: 5.715

5.  The role of Bcl-2 family members in the progression of cutaneous melanoma.

Authors:  Jason A Bush; Gang Li
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias.

Authors:  Anneli R Bowen; Adrianne N Hanks; Kelley J Murphy; Scott R Florell; Douglas Grossman
Journal:  Am J Dermatopathol       Date:  2004-06       Impact factor: 1.533

Review 7.  Targeting Mcl-1 for the therapy of cancer.

Authors:  Bridget A Quinn; Rupesh Dash; Belal Azab; Siddik Sarkar; Swadesh K Das; Sachin Kumar; Regina A Oyesanya; Santanu Dasgupta; Paul Dent; Steven Grant; Mohamed Rahmani; David T Curiel; Igor Dmitriev; Michael Hedvat; Jun Wei; Bainan Wu; John L Stebbins; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Investig Drugs       Date:  2011-08-19       Impact factor: 6.206

8.  Altered mRNA expression related to the apoptotic effect of three xanthones on human melanoma SK-MEL-28 cell line.

Authors:  Jing J Wang; Wei Zhang; Barbara J S Sanderson
Journal:  Biomed Res Int       Date:  2013-09-23       Impact factor: 3.411

9.  A melanoma molecular disease model.

Authors:  Smruti J Vidwans; Keith T Flaherty; David E Fisher; Jay M Tenenbaum; Michael D Travers; Jeff Shrager
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

10.  Expression and function of bcl-2 proteins in melanoma.

Authors:  Jürgen Eberle; Amir M Hossini
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.